Wesley Winn
Direktor/Vorstandsmitglied bei University of Central Florida
Profil
Wesley Winn is currently the Director at the University of Central Florida and the Operating Advisor at Symbiosis Capital Management LLC.
He previously worked as the Senior Director at Dendreon Pharmaceuticals LLC, Director at Micronoma, Inc., Vice President at Hyperion Therapeutics, Inc., Senior Vice President at Global Blood Therapeutics, Inc., and Head/Vice President at Thrombogenics, Inc. He holds an MBA from the University of California, Berkeley, an undergraduate degree from the University of Central Florida, and a graduate degree from John Hopkins University Atlantic Basin Policy Institute.
Aktive Positionen von Wesley Winn
| Unternehmen | Position | Beginn |
|---|---|---|
Symbiosis Capital Management LLC
 Symbiosis Capital Management LLC Investment ManagersFinance Symbiosis Capital Management LLC (SymBiosis) is a venture capital firm founded in 2019. The firm is headquartered in Bentonville, Arkansas. | Berater | 19.07.2022 |
| University of Central Florida | Direktor/Vorstandsmitglied | 01.07.2015 |
Ehemalige bekannte Positionen von Wesley Winn
| Unternehmen | Position | Ende |
|---|---|---|
Dendreon Pharmaceuticals LLC
 Dendreon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Dendreon Pharmaceuticals LLC is a commercial-stage biopharmaceutical company that specializes in developing, manufacturing, and commercializing cell therapies. Dendreon Pharmaceuticals is based in Seal Beach, CA. The private company is a pioneer in cellular therapy, targeting cancer and transforming lives. Dendreon has proven expertise in cellular therapy and ensures product quality through its experience in the field. The company was founded in 1992 by Edgar G. Engleman and Samuel Strober, and the CEO is John C O'Neill. | Corporate Officer/Principal | - |
Thrombogenics, Inc.
 Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The company is based in New York, NY. | Corporate Officer/Principal | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| HYPERION THERAPEUTICS INC | Corporate Officer/Principal | - |
Micronoma, Inc.
 Micronoma, Inc. Medical/Nursing ServicesHealth Services Micronoma, Inc. is a cancer-detection company that uses signals from circulating microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology. Micronoma is headquartered in San Diego, CA. The company aims to revolutionize and advance the practice of early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients' needs are identified and addressed by their clinicians at the earliest stage for a better chance to live longer, healthier lives. The company was founded in 2019 by Sandrine Miller-Montgomery, Greg Poore, Rob Knight, and Magda Marquet. Sandrine Miller-Montgomery has been the CEO since 2019. | Direktor/Vorstandsmitglied | - |
Ausbildung von Wesley Winn
| University of California, Berkeley | Masters Business Admin |
| University of Central Florida | Undergraduate Degree |
| John Hopkins University Atlantic Basin Policy Institute | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
Dendreon Pharmaceuticals LLC
Dendreon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Dendreon Pharmaceuticals LLC is a commercial-stage biopharmaceutical company that specializes in developing, manufacturing, and commercializing cell therapies. Dendreon Pharmaceuticals is based in Seal Beach, CA. The private company is a pioneer in cellular therapy, targeting cancer and transforming lives. Dendreon has proven expertise in cellular therapy and ensures product quality through its experience in the field. The company was founded in 1992 by Edgar G. Engleman and Samuel Strober, and the CEO is John C O'Neill. | Health Technology |
Micronoma, Inc.
Micronoma, Inc. Medical/Nursing ServicesHealth Services Micronoma, Inc. is a cancer-detection company that uses signals from circulating microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology. Micronoma is headquartered in San Diego, CA. The company aims to revolutionize and advance the practice of early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients' needs are identified and addressed by their clinicians at the earliest stage for a better chance to live longer, healthier lives. The company was founded in 2019 by Sandrine Miller-Montgomery, Greg Poore, Rob Knight, and Magda Marquet. Sandrine Miller-Montgomery has been the CEO since 2019. | Health Services |
Symbiosis Capital Management LLC
Symbiosis Capital Management LLC Investment ManagersFinance Symbiosis Capital Management LLC (SymBiosis) is a venture capital firm founded in 2019. The firm is headquartered in Bentonville, Arkansas. | Finance |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Thrombogenics, Inc.
Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The company is based in New York, NY. | Commercial Services |
